Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of OPT-302 +/- Ranibizumab in Wet AMD
NCT02543229Phase 1Completed
- Sponsor
- Opthea Limited
- Start
- Jul 2015
- Primary completion
- Feb 2017
- Modality
- Antibody Fragments, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sozinibercept in exudative macular degeneration (6 cohorts), sponsored by Opthea Limited. Primary endpoint: Safety (Adverse Events). Started Jul 2015; status: completed.
02
Drugs
sozinibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT02543229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02543229.